ArticleClinical case reports2026
A Rare Case Report of Antisynthetase Syndrome With Progressive Myopathy and Interstitial Lung Disease in a 38-Year-Old Male.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Rare Case Report of Antisynthetase Syndrome With Progressive Myopathy and Interstitial Lung Disease in a 38-Year-Old Male.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisynthetase syndrome is a rare autoimmune disorder characterized by a range of clinical features, most commonly associated with autoantibodies targeting aminoacyl-tRNA synthetases. The condition typically presents with a combination of symptoms, including myositis, arthritis, Raynaud's phenomenon, "mechanic's hands," fever, and interstitial lung involvement. Pulmonary manifestations, particularly interstitial lung disease (ILD), are significant prognostic determinants. Management often involves a combination of immunosuppressive agents to address both muscular and respiratory complications. We report the case of a 38-year-old man who developed progressive proximal muscle weakness, arthralgia, Raynaud's phenomenon, and ILD. Laboratory tests indicated elevated muscle enzymes, and anti-Jo-1 antibodies were detected on repeat testings. Electromyography supported a diagnosis of myopathy, while high-resolution computed tomography confirmed ILD. He was treated with corticosteroids, additional immunosuppressants, and plasmapheresis, which resulted in partial symptomatic improvement. Rituximab was considered a potential future treatment option. This case emphasizes the importance of early recognition and prompt, intensive immunosuppressive therapy, along with careful clinical monitoring, to improve outcomes for patients with severe antisynthetase syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.